Dynamic Advisor Solutions LLC Raises Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Dynamic Advisor Solutions LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 7.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,406 shares of the medical instruments supplier’s stock after purchasing an additional 101 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Becton, Dickinson and Company were worth $322,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Bank of Jackson Hole Trust purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $25,000. REAP Financial Group LLC grew its stake in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 55 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 54 shares during the period. Nexus Investment Management ULC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $34,000. Finally, Hopwood Financial Services Inc. purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $39,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.8%

NYSE BDX opened at $168.54 on Friday. The firm has a market cap of $48.30 billion, a PE ratio of 32.16, a price-to-earnings-growth ratio of 1.27 and a beta of 0.25. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average price of $180.23 and a 200 day moving average price of $211.63.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. Becton, Dickinson and Company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.17 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.47%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 79.39%.

Insiders Place Their Bets

In related news, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president now directly owns 4,575 shares of the company’s stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now directly owns 4,887 shares in the company, valued at $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on BDX. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 1st. Citigroup lowered shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and decreased their price objective for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Piper Sandler lowered shares of Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Morgan Stanley reduced their price target on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Finally, Barclays reduced their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research note on Tuesday, June 3rd. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $219.22.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.